Loading
The largest single pathology series of acinar cell carcinoma, from a European network, confirmed which stains identify the tumour, described its variants and showed that stage at diagnosis is what determines survival.
Multicentre European series of 62 acinar cell carcinomas of the pancreas with detailed morphology, immunohistochemistry and follow-up. The study compared the sensitivity of trypsin, chymotrypsin, lipase and BCL10 as markers of acinar differentiation, characterised mixed acinar-neuroendocrine and acinar-ductal tumours, and examined the acinar cell cystadenocarcinoma variant.
Survival was better than in ductal adenocarcinoma but depended strongly on stage: patients with localised, resected tumours could survive for years while metastatic disease behaved aggressively. Trypsin and BCL10 were the most useful diagnostic markers.
The paper underpins the WHO diagnostic criteria for acinar cell carcinoma and its variants and supports aggressive surgery for localised disease.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Pancreatic ductal adenocarcinoma.